News
With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...
Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...
Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...
Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...
Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed ...
Merck (MRK) announced a bold cost-cutting strategy aiming to save $3 billion annually by 2027, reflecting a major operational ...
Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...
Vinay Prasad, a top FDA official, suddenly departed after a series of controversial decisions about a Duchenne gene therapy ...
The scale of the Merck layoffs has not been revealed, but the company indicated that it would target roles in the ...
Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results